Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT9IK2Z)

• DTT Name: N-methyl-D-aspartate receptor (NMDAR)
• Synonyms: NMDA-R
• Gene Name: NMDAR
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T69494

Molecular Interaction Atlas (MIA) of This DTT

12 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Benzphetamine	DMIJATC	Obesity	5B81	Approved	[2]
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[3]
Felbamate	DM1V5ZS	Epilepsy	8A60-8A68	Approved	[4]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[5]
Ketamine	DMT5HA4	Anaesthesia	9A78.6	Approved	[6]
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[1]
Levorphanol	DMGS80V	Pain	MG30-MG3Z	Approved	[7]
Magnesium	DMU4ORS	Ischemic stroke	8B11.5Z	Approved	[8]
Magnesium Sulfate	DMVEK07	Acute pain	MG31	Approved	[9]
Memantine	DMD9WSC	Alzheimer disease	8A20	Approved	[10]
Nitrous oxide	DMTHWBI	Anxiety disorder	6B00-6B0Z	Approved	[11]
Orphenadrine	DMW542E	Parkinson disease	8A00.0	Approved	[12]

25 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AXS-05	DM6WZG8	Depression	6A70-6A7Z	Phase 3	[13]
Dexanabinol	DMRH291	Traumatic brain injury	NA07.Z	Phase 3	[14]
Esketamine	DMVU687	Depression	6A70-6A7Z	Phase 3	[15]
GLYX-13	DMOHUR2	Major depressive disorder	6A70.3	Phase 3	[15]
REL-1017	DM34GOF	Major depressive disorder	6A70.3	Phase 3	[16]
Remacemide	DM3YXP8	Pain	MG30-MG3Z	Phase 3	[17]
NBTX-001	DM3MJUS	Post-traumatic stress disorder	6B40	Phase 2/3	[15]
AGN-241751	DM4KOAC	Major depressive disorder	6A70.3	Phase 2	[18]
Apimostinel	DM7IGO9	Major depressive disorder	6A70.3	Phase 2	[15]
AV-101	DMN7VK1	Major depressive disorder	6A70.3	Phase 2	[19]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[20]
CNS-5161	DM16KJ3	Neuropathic pain	8E43.0	Phase 2	[20]
CP101	DM8X5Q1	Autism spectrum disorder	6A02	Phase 2	[21]
Dimiracetam	DM96NHM	Neuropathic pain	8E43.0	Phase 2	[22]
MDL-27192	DM9FXU7	Epileptic seizures	8A61-8A6Z	Phase 2	[23]
Neramexane	DM3ORVD	Cancer related pain	MG30	Phase 2	[24]
NYX-2925	DM1P60V	Diabetic neuropathy	8C0Z	Phase 2	[25]
NYX-458	DM0BT41	Parkinson disease	8A00.0	Phase 2	[26]
NYX-783	DMAVM2E	Post-traumatic stress disorder	6B40	Phase 2	[27]
SAGE-718	DM9RC7D	Alzheimer disease	8A20	Phase 2	[28]
TRAXOPRODIL MESYLATE	DM1ZQEN	Neurological disorder	6B60	Phase 2	[29]
ADCI	DM59EUY	Epileptic seizures	8A61-8A6Z	Phase 1	[30]
ASP-0777	DM8DBT6	Alzheimer disease	8A20	Phase 1	[31]
AZD6423	DMW4VQF	Suicidal ideation	MB26.A	Phase 1	[32]
BHV-5000	DMM2EZW	Rett syndrome	LD90.4	Phase 1	[25]

24 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midafotel	DM9FJ7N	Cognitive impairment	6D71	Discontinued in Phase 3	[33]
Selfotel	DM3FLIX	Cerebrovascular ischaemia	8B1Z	Discontinued in Phase 3	[7]
AZD6765	DMHZ3DE	Major depressive disorder	6A70.3	Discontinued in Phase 2	[34]
EAA-090	DMC28Y4	Diabetic neuropathy	8C0Z	Discontinued in Phase 2	[20]
SGS-111	DM6XJ9D	Cognitive impairment	6D71	Discontinued in Phase 2	[35]
CGP-37849	DMOULQ4	Neurological disorder	6B60	Discontinued in Phase 1	[36]
Delucemine	DMFUCZQ	Depression	6A70-6A7Z	Discontinued in Phase 1	[37]
S-1746	DMRXB8F	Cerebrovascular ischaemia	8B1Z	Discontinued in Phase 1	[38]
ACEA-1011	DMBY7AZ	Cerebral infarction	8B11.5Z	Terminated	[41]
ACEA-1031	DMCWNVB	Cerebrovascular ischaemia	8B1Z	Terminated	[42]
ACEA-1328	DMEH9OY	Cancer related pain	MG30	Terminated	[24]
ACEA-1416	DMRHSG4	Cerebrovascular ischaemia	8B1Z	Terminated	[43]
CNS-1531	DMZ5N2I	Nervous system disease	8A00-8E7Z	Terminated	[39]
CNS-5788	DMZY0SF	Cerebrovascular ischaemia	8B1Z	Terminated	[44]
FR-115427	DMY2IB8	Cerebrovascular ischaemia	8B1Z	Terminated	[45]
GPI-3000	DMBMAPH	Cerebrovascular ischaemia	8B1Z	Terminated	[46]
IDRA-21	DMG1FQW	Alzheimer disease	8A20	Terminated	[47]
L-689560	DMCVY4U	Neurodegenerative disorder	8A20-8A23	Terminated	[48]
L-698544	DMLRBN1	Alzheimer disease	8A20	Terminated	[49]
LY-274614	DMG79NT	Dementia	6D80-6D86	Terminated	[50]
M-241247	DMIY51U	Cerebrovascular ischaemia	8B1Z	Terminated	[51]
NPS-1392	DMTWXE3	Cerebrovascular ischaemia	8B1Z	Terminated	[52]
PD-158473	DMS1XK5	Cerebrovascular ischaemia	8B1Z	Terminated	[53]
PD-159913	DMJ5STO	Cerebrovascular ischaemia	8B1Z	Terminated	[39]

3 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD-529	DMBI1H2	Neuropathic pain	8E43.0	Preclinical	[39]
ADX-2 series	DM2WKDN	Schizophrenia	6A20	Preclinical	[40]
ED-1812	DMG4DHX	Pain	MG30-MG3Z	Preclinical	[39]

2 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACPC	DMAZLWR	Neurological disorder	6B60	Investigative	[54]
Aptiganel HCl	DMF1264	Ischemic stroke	8B11.5Z	Investigative	[7]

References

• [1] Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
• [2] Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
• [3] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [4] Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
• [5] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [6] Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
• [7] Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
• [8] Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
• [9] Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
• [10] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
• [11] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
• [12] Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
• [13] Clinical pipeline report, company report or official report of Axsome Therapeutics.
• [14] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238.
• [17] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [18] Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799-808.
• [19] Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc.
• [20] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [21] The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17.
• [22] Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94.
• [23] Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54.
• [24] Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71.
• [25] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [26] NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Mov Disord. 2020 Apr;35(4):640-649.
• [27] Clinical pipeline report, company report or official report of Aptinyx.
• [28] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [29] The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005 Dec;22(12):1428-43.
• [30] The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
• [31] US patent application no. 2011,0262,442, Compositions for treating cns disorders.
• [32] Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009.
• [33] D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci Lett. 1990 Jun 8;113(3):315-21.
• [34] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [35] Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010 February; 31(2): 66.
• [36] The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6.
• [37] NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann N Y Acad Sci. 1999;890:450-7.
• [38] 1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77.
• [39] WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors.
• [40] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [41] NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4.
• [42] In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81.
• [43] Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr;37(4):295-302.
• [44] Identification and characterization of a potential ischemia-selective N-methyl-D-aspartate (NMDA) receptor ion-channel blocker, CNS 5788. Bioorg Med Chem Lett. 2001 Feb 26;11(4):501-4.
• [45] Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995 Feb 9;185(2):107-10.
• [46] Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke. 1998 Apr;29(4):824-9.
• [47] IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13.
• [48] Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992 May;41(5):923-30.
• [49] 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408.
• [50] The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75.
• [51] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415)
• [52] Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1915-20.
• [53] Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J Pharm Sci. 2002 Dec;91(12):2579-87.
• [54] 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8.